Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | ACLY | P53396 | 5/20 | 0.51 |
| ▸ | WDR5 | P61964 | 4/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005134 | 0.80 | NPC1 (0.66) | ACLYWDR5TSHRMEN1KMT2A | |
| SCHEMBL2766570 | 0.79 | ERBB2 (0.68) | HSP90AA1HSP90AB1ERBB2ACLYHKDC1 | |
| SCHEMBL22005133 | 0.79 | ACLY (0.62) | ACLYMCL1TSHRHPGD | |
| SCHEMBL22004216 | 0.76 | ACLY (0.55) | ACLYMCL1TSHRHPGD | |
| SCHEMBL22021605 | 0.76 | ACLY (0.66) | ACLYWDR5 | |
| SCHEMBL22004211 | 0.74 | ACLY (0.64) | ACLYWDR5 | |
| SCHEMBL29859117 | 0.73 | WDR5 (0.55) | ACLYWDR5PTGES2 | |
| SCHEMBL2765953 | 0.73 | GLO1 (0.55) | — | |
| SCHEMBL4143797 | 0.72 | KIF11 (0.46) | MCL1TSHRHPGDMEN1KMT2A | |
| SCHEMBL28591171 | 0.71 | APP (0.61) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | HSP90AA1 2069/4885HSP90AB1 1582/4885ERBB2 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.